Platelet‐derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate

Abstract

Although it is unknown whether the base change described above represents a true mutation or a single nucleotide polymorphism, the fact that this change was absent in our control specimens suggests that this mutation may be oncogenic in nature and may make imatinib mesylate a possible therapeutic option in MCC.